Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive Groups and stocks within Health Care and Technology: Biotech, Mid-Cap, Biotech, Small-Cap, Semiconductors, Large-Cap, and Semiconductors, Mid-Cap..

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive Groups and stocks within Health Care and Technology: Biotech, Mid-Cap, Biotech, Small-Cap, Semiconductors, Large-Cap, and Semiconductors, Mid-Cap..

MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

U.S. Equity Strategy: Upgrading Health Care to Overweight

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

Acadia Pharmaceuticals / Equity Bottom-Up

We took another look at P2 trial design for <a href="https://www.smartkarma.com/entities/10370" target="_blank" data-smartkarma-citation="entities:10370:1">Acadia Pharmaceuticals Inc (ACAD US)</a> Alzheimer's disease Psychosis ADP trial (results expected later this month) . It is single-center study, placebo controlled, double-blinded. Sample size is similar to successful Parkinson's psychosis, PDP trial. Dose 40 mg/day is similar to PDP P3. Duration of treatment is double, 12 weeks vs. 6 weeks in P3 PDP trial. The primary endpoint in ADP trial (Neuropsychiatry-nursing home inventory) is a questionnaire…

We took another look at P2 trial design for Acadia Pharmaceuticals Inc (ACAD US) Alzheimer's disease Psychosis ADP trial (results expected later this month) . It is single-center study, placebo controlled, double-blinded. Sample size is similar to successful Parkinson's psychosis, PDP trial. Dose 40 mg/day is similar to PDP P3. Duration of treatment is double, 12 weeks vs. 6 weeks in P3 PDP trial. The primary endpoint in ADP trial (Neuropsychiatry-nursing home inventory) is a questionnaire…

Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.

We listened to <a href="https://www.smartkarma.com/entities/23716" target="_blank" data-smartkarma-citation="entities:23716:1">Cerecor Inc (CERC US)</a> management's conference call (<a href="http://ir.cerecor.com/ir-calendar/detail/756/topline-phase-2-results-for-cerc-301s-phase-2-trial-in" target="_blank">link</a>) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (<a href="http://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study" target="_blank">link to press release</a>). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (link to press release). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

United States

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acadia Pharmaceuticals (ACAD US)

MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive...

Vermilion Research

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Vermilion Research

Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.

We took another look at P2 trial design for Acadia Pharmaceuticals Inc (ACAD US) Alzheimer's disease Psychosis ADP trial (results expected later...

Dr. Bhavneesh Sharma, MD, MBA

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)